Winter Erica, Schliebner Scott
Pfizer Inc, Clinical Pharmacology, New York, NY, USA.
PRA Health Sciences, Center for Rare Diseases, Seattle, WA, USA.
Curr Rev Clin Exp Pharmacol. 2022;17(1):39-45. doi: 10.2174/1574884716666210316120615.
Characterized by small, highly heterogeneous patient populations, rare disease trials magnify the challenges often encountered in traditional clinical trials. In recent years, there have been increased efforts by stakeholders to improve drug development in rare diseases through novel approaches to clinical trial designs and statistical analyses. We highlight and discuss some of the current and emerging approaches aimed at overcoming challenges in rare disease clinical trials, with a focus on the ultimate stakeholder, the patient.
罕见病试验的特点是患者群体规模小且高度异质,这放大了传统临床试验中经常遇到的挑战。近年来,利益相关者加大了努力,通过采用新颖的临床试验设计和统计分析方法来改善罕见病药物研发。我们重点介绍并讨论一些旨在克服罕见病临床试验挑战的现有及新出现的方法,重点关注最终利益相关者——患者。